| GERON CORP. (DEL.) DL-001 |
| USA |
| Gesundheit |
| US3741631036 / 902213 |
| GON (Frankfurt) / GERN (NASDAQ) |
| FRA:GON, ETR:GON, GON:GR, NASDAQ:GERN |
| - |
| https://www.geron.com/ |
|
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the tre..
>Volltext.. |
| 686.61 Mio. EUR |
| 642.04 Mio. EUR |
| 182.18 Mio. EUR |
| -32.35 Mio. EUR |
| -62.25 Mio. EUR |
| -0.09 EUR |
| 224.22 Mio. EUR |
| 57.47 Mio. EUR |
| -101.86 Mio. EUR |
| 4.3 |
| 28.3% |
| 18.08% |
| - |
| - |
| - |
| - |
| GERON |
| 21.10.26 |
|